Hype in Genes
By Matthew Herper,
Forbes
| 07. 11. 2007
Gene celeb Craig Venter is making new breakthroughs at a new institute. Let's hope it doesn't end up like his last one.
J Craig Venter secured his place in the scientific firmament seven years ago when he nearly outran the U.S. government in the race to map the human genome. He's aiming impossibly high again, making big headlines for transplanting the entire genome of one species of bacterium into another. It was hailed by several scientists as a step toward producing the first man-made organism that, according to Venter, could as soon as five years from now help solve global warming by reducing our reliance on fossil fuels.
Venter's transplanting trick was another wow moment at his 500-person gene machine, which goes by an easy-to-remember name, the J. Craig Venter Institute. Its $200 million in assets is funded in part by gains from his biotech business ventures. Venter, 60, is one of the two most mentioned researchers in a recent textbook on recombinant DNA.
Being the Bono of genetics allows him to fund audacious ideas that might otherwise be starved...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...